Neuroendocrine Carcinoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Neuroendocrine Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions.
Neuroendocrine carcinoma (NEC) is a rare type of cancer that arises from neuroendocrine cells, which are cells that have both nerve and hormone functions. NEC can occur in various organs, such as the lungs, pancreas, stomach, intestines, appendix, rectum, breast, kidney, ovaries, or testicles. NEC can be classified into well-differentiated or poorly differentiated tumors, depending on how they look under the microscope and how fast they grow. Well-differentiated NECs are usually slow-growing and have a better prognosis than poorly differentiated NECs, which are aggressive and have a worse prognosis. NECs can also be functional or nonfunctional, depending on whether they produce excess hormones that cause symptoms. Functional NECs can cause carcinoid syndrome, which is a group of symptoms such as flushing, diarrhea, wheezing, and heart problems. Nonfunctional NECs do not cause any hormonal symptoms. The diagnosis and treatment of a NEC depends on the location, type, grade, stage, and hormone status of the tumor.
The Neuroendocrine Carcinoma drugs in development market research report provide comprehensive information on the therapeutics under development for Neuroendocrine Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroendocrine Carcinoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Neuroendocrine Carcinoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 29 molecules, with 28 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Neuroendocrine Carcinoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Neuroendocrine Carcinoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Neuroendocrine Carcinoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncADC Therapeutics SA
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Elicera Therapeutics AB
Exelixis Inc
F. Hoffmann-La Roche Ltd
GSK plc
Harbour BioMed (Guangzhou) Co Ltd
Hutchison MediPharma Ltd
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Leads Biolabs Inc
Merck & Co Inc
Merck KGaA
Oryzon Genomics SA
Qilu Pharmaceutical Co Ltd
SciClone Pharmaceuticals Holdings Ltd
Shanghai Jiao Tong University School of Medicine
Shanghai Junshi Biosciences Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Taiho Oncology Inc
Takeda Pharmaceutical Co Ltd
Vyriad Inc
Wuxi Biocity Biopharma Co Ltd
Xencor Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Neuroendocrine Carcinoma reports